1. Is the use of antibiotic stewardship measures in the context of specialized outpatient palliative care sensible and feasible? An interview-based study.
- Author
-
Kaiser U, Kaiser F, Schmidt J, Vehling-Kaiser U, and Hitzenbichler F
- Subjects
- Humans, Germany, Ambulatory Care methods, Ambulatory Care standards, Interviews as Topic methods, Anti-Bacterial Agents therapeutic use, Female, Male, Middle Aged, Palliative Care methods, Palliative Care standards, Antimicrobial Stewardship methods, Antimicrobial Stewardship standards, Qualitative Research
- Abstract
Background: Specialized outpatient palliative care (SAPV) is a component of palliative care in Germany, which assists approximately 10% of palliative patients. The majority of these patients have a malignant disease and are at increased risk of complications or severe infection. Antibiotic stewardship (ABS) measures are implemented to optimize antibiotic administration; however, there is little data available in this area, particularly for SAPV. Therefore, we examined the extent to which ABS measures can be meaningfully used or implemented in SAPV., Methods: After establishing a corresponding interview guide, 15 experts from specialized areas were interviewed on this subject by the Institute for Market Research in Healthcare Munich (IMIG) through audio-registered individual interviews. The interviews were analyzed using the qualitative content analysis method according to Mayring., Results: All 15 experts participated. The primary benefits cited were greater safety in the prescription and decision-making process for antibiotics in the areas of SAPV and improved quality of life. The implementation of continuous ABS measures for SAPV was considered difficult in some cases and linked to certain prerequisites, such as supportive advice from existing systems. The possibility of further training for SAPV members in the area of ABS was considered particularly advantageous., Conclusions: The implementation of ABS measures in SAPV is feasible in principle; however, it is difficult to implement under the current conditions. Close cooperation with an existing external ABS expert/team will be helpful. This will provide more security for a small, but relevant proportion of SAPV patients, and for the SAPV team treating them., Competing Interests: Declarations. Ethics approval and consent to participate: After consultation with the Ethics Committee of the University of Regensburg, no professional advice and consequently no vote by the Ethics Committee was required for the present study in accordance with Sect. 15 of the Professional Code of Conduct for Physicians in Bavaria. Consent for publication: Not applicable. Competing interests: U.K., J.S., and U.VK. declare no competing interests; F.H. has received lecture fees from Pfizer, and travel expenses and congress fees have been covered by Tillotts Pharma and Gilead Sciences; F.K. has conducted consulting work for Elsevier, Astellas, GSK, MSD, Novartis, Pierre Fabre, Sanofi, and Servier., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF